Low stent thrombosis risk with the XIENCE VA® everolimus-eluting coronary stent: Evidence from randomized and single-arm clinical trials

Journal of Interventional Cardiology

Volumn 24, Issue 4, 2011, Pages 326-341

  Bezenek, Susan ^a   Hermiller, James ^b   Lansky, Alexandra ^c   Yaqub, Manejeh ^a   Hattori, Kyoko ^a   Cao, Sherry ^a   Sood, Poornima ^a   Sudhir, Krishnakutty ^a  

^a ABBOTT VASCULAR   (United States)

^b Heart Center of Indiana   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMITOTIC AGENT; CLOPIDOGREL; EVEROLIMUS; HEXAFLUOROPROPYLENE; PACLITAXEL; POLYMER; RAPAMYCIN; TICLOPIDINE; UNCLASSIFIED DRUG; VINYLIDENE FLUORIDE; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCOMPATIBILITY; CLINICAL PROTOCOL; CORONARY STENT; DIABETIC PATIENT; DRUG ELUTING STENT; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SMOOTH MUSCLE FIBER; STENT THROMBOSIS;

CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 80051549272     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00628.x     Document Type: Article

References (94)

1. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48 (12): 2584-2591. (Pubitemid 44881238)
2. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369 (9562): 667-678. (Pubitemid 46281313)
3. Camenzind E, Steg PG, Wijns W,. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007; 115 (11): 1440-1455; discussion 1455. (Pubitemid 46648381)
4. Farb A, Boam AB,. Stent thrombosis redux-the FDA perspective. N Engl J Med 2007; 356 (10): 984-987. (Pubitemid 46376798)
5. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375 (9710): 201-209.
6. Lemesle G, Maluenda G, Collins SD, et al. Drug-eluting stents: Issues of late stent thrombosis. Cardiol Clin 2010; 28 (1): 97-105.
7. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: Five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50 (14): 1299-1304. (Pubitemid 47454687)
8. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 (14): 1315-1323. (Pubitemid 37186209)
9. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109 (16): 1942-1947. (Pubitemid 38544483)
10. Weisz G, Leon MB, Holmes DR, Jr,., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006; 47 (7): 1350-1355.
11. Garratt KN, Edwards WD, Kaufmann UP, et al. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: Analysis of tissue obtained from 73 patients by directional atherectomy. J Am Coll Cardiol 1991; 17 (2): 442-448.
12. Schwartz RS, Holmes DR, Jr, Topol EJ,. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20 (5): 1284-1293.
13. Farb A, Kolodgie FD, Hwang JY, et al,. Extracellular matrix changes in stented human coronary arteries. Circulation 2004; 110 (8): 940-947. (Pubitemid 39128619)
14. Finn AV, Joner M, Nakazawa G, et al,. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115 (18): 2435-2441. (Pubitemid 46717966)
15. Ormiston JA, Serruys PW, Regar E, et al,. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008; 371 (9616): 899-907. (Pubitemid 351384734)
16. Ormiston JA, Serruys PW,. Bioabsorbable coronary stents. Circ Cardiovasc Interv 2009; 2 (3): 255-260.
17. Kastrati A, Mehilli J, Dirschinger J, et al,. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103 (23): 2816-2821. (Pubitemid 32550070)
18. Pache, J, Kastrati A, Mehilli J, et al,. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41 (8): 1283-1288. (Pubitemid 36438988)
19. Briguori C, Sarais C, Pagnotta P, et al,. In-stent restenosis in small coronary arteries: Impact of strut thickness. J Am Coll Cardiol 2002; 40 (3): 403-409. (Pubitemid 34833152)
20. Doostzadeh J, Clark LN, Bezenek S, et al,. Recent progress in percutaneous coronary intervention: Evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis 2010; 21 (1): 46-56.
21. Smits P,. Compare Trial. In TCT. 2009. San Francisco, CA. USA.
22. Joner M, Quee SC, Coleman L, et al,. Abstract 2460: Competitive comparison of reendothelialization in drug eluting stents. Circulation 2006; 114 (Supplement II): 502.
23. Joner M, Nakazawa G, Finn AV, et al,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52 (5): 333-342. (Pubitemid 352001347)
24. Doostzadeh J, Bezenek S, Cheong WF, et al,. Clinical trials in interventional cardiology: Focus on XIENCE V drug-eluting stent. In, Gad SC, ed. Clinical Trials Handbook. Hoboken: John Wiley & Sons, Inc, 2009, pp. 397-433.
25. Axel DI, Kunert W, Goggelmann C, et al,. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96 (2): 636-645. (Pubitemid 27329445)
26. Vasquez EM,. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57 (5): 437-448; quiz 449-451.
27. Steffel J, Latini RA, Akhmedov A, et al,. Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 2005; 112 (13): 2002-2011. (Pubitemid 41377420)
28. Finn AV, Kolodgie FD, Harnek J, et al,. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 2005; 112 (2): 270-278. (Pubitemid 40982311)
29. Virmani R, Guagliumi G, Farb A, et al,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109 (6): 701-705. (Pubitemid 38222887)
30. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48 (1): 193-202. (Pubitemid 43929240)
31. Finn AV, Nakazawa G, Joner M, et al,. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27 (7): 1500-1510. (Pubitemid 46986103)
32. Ding N, Pacetti SD, Tang FW, et al,. XIENCE V™ stent design and rationale. J Interv Cardiol 2009; 22: S18-S27.
33. Rhee RY, Gloviczki P, Cambria RA, et al,. Experimental evaluation of bleeding complications, thrombogenicity and neointimal characteristics of prosthetic patch materials used for carotid angioplasty. Cardiovasc Surg 1996; 4 (6): 746-752. (Pubitemid 27061903)
34. Pedrini L, Dondi M, Magagnoli A, et al,. Evaluation of thrombogenicity of fluoropassivated polyester patches following carotid endarterectomy. Ann Vasc Surg 2001; 15 (6): 679-683. (Pubitemid 33115653)
35. Ashton EA,. Proceedings of the 12th Euro Conference on biomaterials, Portugal, September 1995. 10-13.
36. Guidoin R, Marois Y, Zhang Z, et al,. The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. ASAIO J 1994; 40 (3): M870-M879. (Pubitemid 24364325)
37. Kottke-Marchant K, Anderson JM, Umemura Y, et al,. Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses. Biomaterials 1989; 10 (3): 147-155. (Pubitemid 19120668)
38. Ting-Yu Liu EA,. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym Adv Technol 2005; 16 (5): 413-419.
39. Petersen RJ, Rozelle LT,. Ethylcellulose perfluorobutyrate: A highly non-thrombogenic fluoropolymer for gas exchange membranes. Trans Am Soc Artif Intern Organs 1975; 21: 242-248.
40. Hong R, Zhang Y, Liu Y, et al,. [Effects of extremely low frequency electromagnetic fields on DNA of testicular cells and sperm chromatin structure in mice]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2005; 23 (6): 414-417.
41. Stone GW, Rizvi A, Newman W, et al,. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362 (18): 1663-1674.
42. Hermiller J,. Low stent thrombosis rates in 5,054 'real-world' patients from XIENCE V USA. In EuroPCR. Paris, France, 2010.
43. Kereiakes DJ, Choo JK, Young JJ, et al,. Thrombosis and drug-eluting stents: A critical appraisal. Rev Cardiovasc Med 2004; 5 (1): 9-15. (Pubitemid 38344495)
44. Orford JL, Lennon R, Melby S, et al,. Frequency and correlates of coronary stent thrombosis in the modern era: Analysis of a single center registry. J Am Coll Cardiol 2002; 40 (9): 1567-1572. (Pubitemid 35253633)
45. Luscher TF, Steffel J, Eberli FR, et al,. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 2007; 115 (8): 1051-1058. (Pubitemid 46328299)
46. Moussa I, Di Mario C, Reimers B, et al,. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29 (1): 6-12. (Pubitemid 27028713)
47. Schuhlen H, Kastrati A, Dirschinger J, et al,. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98 (2): 104-111. (Pubitemid 28317889)
48. Cheneau E, Leborgne L, Mintz GS, et al,. Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study. Circulation 2003; 108 (1): 43-47. (Pubitemid 36859018)
49. Cutlip DE, Baim DS, Ho KK, et al,. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103 (15): 1967-1971. (Pubitemid 32322224)
50. Chieffo A, Bonizzoni E, Orlic D, et al,. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004; 109 (22): 2732-2736. (Pubitemid 38737920)
51. Park DW, Park SW, Park KH, et al,. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98 (3): 352-356.
52. Fujii K, Carlier SG, Mintz GS, et al,. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study. J Am Coll Cardiol 2005; 45 (7): 995-998. (Pubitemid 40432428)
53. Farb A, Burke AP, Kolodgie FD, et al,. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108 (14): 1701-1706. (Pubitemid 37243657)
54. Nakazawa G, Finn AV, Joner M, et al,. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118 (11): 1138-1145.
55. Silva JA, Ramee SR, White CJ, et al,. Primary stenting in acute myocardial infarction: Influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999; 138 (3 Pt 1): 446-455. (Pubitemid 29428766)
56. Iakovou I, Schmidt T, Bonizzoni E, et al,. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293 (17): 2126-2130. (Pubitemid 40617065)
57. Ong AT, Hoye A, Aoki J, et al,. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45 (6): 947-953. (Pubitemid 40342824)
58. Kuchulakanti PK, Chu WW, Torguson R, et al,. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 2006; 113 (8): 1108-1113.
59. McFadden EP, Stabile E, Regar E, et al,. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364 (9444): 1519-1521. (Pubitemid 39410418)
60. Wenaweser P, Dorffler-Melly J, Imboden K, et al,. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45 (11): 1748-1752. (Pubitemid 40779850)
61. Grines CL, Bonow RO, Casey DE, Jr., et al,. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007; 138 (5): 652-655.
62. Gurbel PA, Kandzari DE,. Stent thrombosis associated with first-generation drug-eluting stents: Issues with antiplatelet therapy. Neth Heart J 2007; 15 (4): 148-150. (Pubitemid 47253682)
63. Campo G, Valgimigli M, Gemmati D, et al,. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY study. J Am Coll Cardiol 2006; 48 (11): 2178-2185. (Pubitemid 44873056)
64. Cuisset T, Frere C, Quilici J, et al,. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4 (3): 542-549.
65. Serebruany VL, Steinhubl SR, Berger PB, et al,. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45 (2): 246-251. (Pubitemid 40094733)
66. Gurbel PA, Bliden KP, Hayes KM, et al,. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45 (9): 1392-1396. (Pubitemid 40615608)
67. Wiviott SD, Braunwald E, McCabe CH, et al,. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20): 2001-2015. (Pubitemid 350106708)
68. Serruys PW, Silber S, Garg S, et al,. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363 (2): 136-146.
69. Smits P,. COMPARE Trial 2 year follow-up. In TCT. Washington, DC, 2010.
70. Okkels LA,. Prospective, randomized trial of everolimus-eluting and sirolimus-eluting stents in patients with coronary artery disease-The SORT-OUT IV trial. In TCT. Washington, DC, 2010.
71. Byrne R,. Two-year outcomes after everolimus-or sirolimus-eluting stents in patients with coronary artery disease in the ISAR-TEST 4 trial. In TCT. Washington, DC, 2010.
72. Silber S,. The zotarolimus-eluting stent: New insights from RESOLUTE All-comers. In TCT. Washington, DC, 2010.
73. Wang F, Stouffer GA, Waxman S, et al,. Late coronary stent thrombosis: Early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 2002; 55 (2): 142-147. (Pubitemid 34127369)
74. Cutlip DE, Windecker S, Mehran R, et al,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115 (17): 2344-2351. (Pubitemid 46685903)
75. Mauri L, Hsieh WH, Massaro JM, et al,. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356 (10): 1020-1029. (Pubitemid 46376802)
76. Moreno R, Fernandez C, Hernandez R, et al,. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45 (6): 954-959. (Pubitemid 40342825)
77. Roukoz H, Bavry AA, Sarkees ML, et al,. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 2009; 122 (6): 581 e1-e10.
78. Wiemer M, Serruys PW, Miquel-Hebert K, et al,. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial. Catheter Cardiovasc Interv 2010; 75 (7): 997-1003.
79. Onuma Y, Serruys PW,. The SPIRIT II study-a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. In ACC. Atlanta, GA, 2010.
80. Stone GW, Midei M, Newman W, et al,. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299 (16): 1903-1913. (Pubitemid 351574920)
81. Cox DA,. Evaluation of thienopyridine compliance and stent thrombosis rates after everolimus-eluting and paclitaxel-eluting stent implantation: 3-year results from the SPIRIT III analysis. In ACC. Atlanta, GA, 2010.
82. Migliorini A, Shehu M, Carrabba N, et al,. Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis. Am J Cardiol 2005; 96 (8): 1110-1112. (Pubitemid 41416604)
83. King S, 3rd, Aversano T, Ballard WL, et al,. ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on clinical competence and training (writing committee to update the 1998 clinical competence statement on recommendations for the assessment and maintenance of proficiency in coronary interventional procedures). Circulation 2007; 116 (1): 98-124. (Pubitemid 47018228)
84. Dawkins KD, Grube E, Guagliumi G, et al,. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112 (21): 3306-3313. (Pubitemid 43739376)
85. Morice MC, Colombo A, Meier B, et al,. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006; 295 (8): 895-904.
86. Kirtane AJ, Patel R, O'Shaughnessy C, et al,. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: Randomized comparison of zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009; 2 (10): 967-976.
87. Stone GW, Ellis SG, Cox DA, et al,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350 (3): 221-231. (Pubitemid 38067635)
88. Windecker S, Remondino A, Eberli FR, et al,. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353 (7): 653-662. (Pubitemid 41175673)
89. Stone GW, Ellis SG, Cannon L, et al,. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294 (10): 1215-1223. (Pubitemid 41352109)
90. Fajadet J, Wijns W, Laarman GJ, et al,. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114 (8): 798-806. (Pubitemid 44268230)
91. Kandzari DE, Leon MB, Popma JJ, et al,. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48 (12): 2440-2447. (Pubitemid 44881222)
92. Serruys P,. Resolute All Comers Trial-a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention primary results. In EuroPCR. Paris, France, 2010.
93. Grube E,. SPIRIT V registry 1 year follow-up. In EuroPCR. Paris, France, 2009.
94. Grube, E,. SPIRIT V diabetic RCT 9 month angiographic and 1 year clinical follow-up. In EuroPCR. Paris, France, 2010.